Changes of Creatinine Clearance in Tenofovir Disoproxil Fumarate plus Ritonavir-boosted Lopinavir Regimen Compared with Nonnucleoside Reverse-Transcriptase Inhibitor Regimen in HIV-infected patients : Two Years Follow Up.

Article Sidebar

PDF
Published: Apr 27, 2018
Keywords:
tenofovir disoproxil fumarate renal toxicity HIV-infected patient

Main Article Content

Sunee Medhajirapath
Medical Physician, Professional Level, Department of Medicine, Surin Hospital, Surin, Thailand

Abstract

Background: In Thailand, combination of tenofovir disoproxil fumarate (TDF) with ritonavir-boosted lopinavir (LPV/r) or nonnucleoside reverse-transcriptase inhibitor (NNRTI) are commonly used for HIV-treatment failure patients. Decreasing of creatinine clearance (CrCl) is one of the most concerned adverse events for TDF. This study aimed to determine the changes in CrCl after two years of TDF combination regimen and compare between LPV/r and NNRTI.
Study design: Retrospective cohort study
Methods: Review data of CrCl and recalculated with MDRD equation from patients in HIV clinic during 1st January 2010 to 31st December 2014 who received TDF combination regimen for two years.
Results: Of 135 patients receiving TDF, there were 39 cases (28.9%) combined with LPV/r and 96 (71.1%) combined with NNRTI (nevirapine or efavirenz). The CrCl before and after two years of TDF use were 92.72 mL/min/1.73m2 and 81.75 mL/min/1.73m , respectively (p<0.001). TDF+LPV/r group had the most decrease of CrCl (15.36 mL/min/1.73m2) and nine in 39 patients (23.1%) decreased CrCl for more than 25 percents. Seventeen in 96 patients in TDF+NNRTI group had decreased CrCl more than 25 percents, representing a relative risk of 1.3 (95%CI 0.6 to 2.7). However, no any patients discontinued from TDF during the study period.
Conclusion: There are greater declines in CrCl after two years with TDF+LPV/r compared with TDF+NNRTI regimen but there are no change in clinical outcome. Further study with longer follow up is needed.

Article Details

How to Cite
Medhajirapath, S. (2018). Changes of Creatinine Clearance in Tenofovir Disoproxil Fumarate plus Ritonavir-boosted Lopinavir Regimen Compared with Nonnucleoside Reverse-Transcriptase Inhibitor Regimen in HIV-infected patients : Two Years Follow Up. MEDICAL JOURNAL OF SISAKET SURIN BURIRAM HOSPITALS, 30(2), 95–104. retrieved from https://he02.tci-thaijo.org/index.php/MJSSBH/article/view/120362
Issue
Vol. 30 No. 2 (2015): May - August 2015
Section
Original Articles

References

1. Hammer SM, Eron J J, Jr., Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. Jama 2008;300:5:555-70.

2. ประพันธ์ ภานุภาค นมล, ทวีทร้พย์ ศิรประภาศิร, วสันต์ จันทราทิตย์, วิชัย เตชะสาธิต, อัจฉรา ธีรรัตน์กุล, กุลกัญญา โชคไพบูลย์กิจ, สมนึก สังฆานุภาพ และคณะ. แนวทางการตรวจวินิจฉัยและ การดูแลรักษาผู้ติดเชื้อเอชไอวีและผู้ป่วยเอดส์ ระดับชาติ ปี พ.ศ. 2553. โรงพิมพ์ชุมนุมสหกรณ์การเกษตรแห่งประเทศไทยจำกัด: ศูนย์พัฒนาระบบบริการยาต้านไวรัสสำหรับ ผู้ติดเชื้อเอชไอวี และผู้ป่วยเอดส์ในประเทศไทย; 2553.

3. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006;42:2:283-90.

4.Verhelst D, Monge M, Meynard JL, Fouqueray B, Mougenot B, Girard PM, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:6:1331-3.

5.Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003;36:8:1070-3.

6. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002;324: 6:342-4.

7. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003;17:6:935-7.

8. Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003;325:6:349-62.

9. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiret- roviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:4:743-6.

10. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005;45:5:804-17.

11. Pierrat A, Gravier E, Saunders C, Caira MV, Ait-Djafer Z, Legras B, et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int 2003;64:4:1425-36.

12. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir- associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008;197:l:102-8.

13. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005;40:8:1194-8.